This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Save the date!
November 6–8, 2023Munich, Germany

Sander Slootweg
Managing Partner at Forbion


Sander is a Founder and Managing Partner at Forbion, a leading European Life Sciences VC firm. In addition to his leading role on its investment team, he is responsible for Fundraising, Investor- and Public Relations at Forbion. On the portfolio management side, he currently serves on the boards of portfolio companies Replimune (REPL), NorthSea (Chair), Xention and Oxyrane.

Sander was a.o. responsible for the sale of Dezima to Amgen in 2015 for up to USD 1.55 billion and Biovex to Amgen in March of 2011 for up to USD 1 billion. In recent years Sander has also served on the boards of Fovea (sold to Sanofi in 2009), uniQure (IPO on Nasdaq in 2014), Argenta (sold to Galapagos in 2010), Pieris (IPO on Nasdaq in 2015), Alantos Pharmaceuticals, Inc. (sold to Amgen in 2007) and Impella (sold to Abiomed in 2005).

Before founding Forbion, he was a co-founder of ABN AMRO Capital Life Sciences in 2000. His other activities at ABN AMRO Bank included buy-out/ growth equities at ABN AMRO Capital, Equity Capital Markets Syndications (HQ Amsterdam) and Financial Institutions Relationship Management Latin America (Regional Office Miami).

Sander holds degrees in Business and Financial Economics from the Free University of Amsterdam and Business Administration from Nijenrode University, The Netherlands.

Agenda Sessions

  • Opening plenary session: Opportunities created by a bear market - There IS a silver lining

  • In collaboration with YVC Collective - Fireside Chat